Dolan Matthew Vincent 4
4 · DEXCOM INC · Filed Mar 17, 2022
Insider Transaction Report
Form 4
DEXCOM INCDXCM
Dolan Matthew Vincent
EVP, Strategy & Corporate Dev
Transactions
- Sale
Common Stock
2022-03-17$450.00/sh−484$217,800→ 6,634 total - Sale
Common Stock
2022-03-15$412.41/sh−1,016$419,009→ 7,804 total - Sale
Common Stock
2022-03-16$425.00/sh−686$291,550→ 7,118 total
Footnotes (2)
- [F1]On December 15, 2021, Mr. Dolan adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Dolan. The shares set forth above were sold pursuant to the 10b5-1 Plan.
- [F2]Included in this number are 6,634 unvested restricted stock units, 2,889 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,048 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 1,697 of which were granted on March 8, 2020 and shall vest through March 8, 2023.